Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

Patel, Sarah; Doerfler, Bethany; Boutros, K; Ng, Samson; Manuel, Machelle; DeSimone, Elayne

doi:10.2147/ijgm.s274568

Cited by 8 publications

(8 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10,11 With its diverse pathophysiological mechanisms and presenting symptoms, there is currently no definitive treatment for IBS beyond supportive treatment and symptomatic relief. [12][13][14] Management of IBS can be classified into dietary modification, modification of gut microbiome, and pharmacotherapy aimed at altering motility, sensation, and intraluminal environment. However, current treatments may have limited long-term benefits, marginal effects on QoL, or bothersome adverse effects.…”

Section: Introductionmentioning

confidence: 99%

“…However, current treatments may have limited long-term benefits, marginal effects on QoL, or bothersome adverse effects. [14][15][16] Burgeoning studies have suggested a relationship between vitamin D deficiency and multiple disease states, including IBS. 17,18 Vitamin D has putative functions in influencing cellular mechanisms, regulating gut microbiome, and modulating immune system and inflammatory processes.…”

Section: Introductionmentioning

confidence: 99%

“…Management of IBS can be classified into dietary modification, modification of gut microbiome, and pharmacotherapy aimed at altering motility, sensation, and intraluminal environment. However, current treatments may have limited long‐term benefits, marginal effects on QoL, or bothersome adverse effects 14–16 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Vitamin D supplementation for irritable bowel syndrome: A systematic review and meta‐analysis

Chong

Yaow

Loh

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Irritable bowel syndrome (IBS) is a prevalent and complex gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits. Observational studies have suggested a relationship between serum vitamin D levels and IBS symptoms. This systematic review and meta‐analysis aimed to investigate the clinical effects of vitamin D supplementation on IBS symptom severity and quality of life (QoL) measures. Methods Medline, Embase, Scopus, Web of Science, and The Cochrane Library databases were systematically searched. Data abstraction and quality assessment were conducted by four authors independently, and discrepancies were resolved through consensus from the senior author. Continuous data were pooled with standardized mean difference (SMD) using the DerSimonian and Laird's random‐effects model. Sensitivity analysis by risk of bias and potentially “predatory” publication were performed as well. Results A total of 685 patients across eight studies were included in the meta‐analysis. Vitamin D supplementation significantly improved IBS symptom severity scale scores, with a SMD of −0.77 (95% confidence interval [CI] −1.47 to −0.07, P = 0.04, I2 = 91%). Improvements in IBS‐QoL scores were also observed, albeit not statistically significant (SMD 0.54; 95% CI −0.34 to 1.41, P = 0.15, I2 = 87%). However, small sample sizes, a relatively young study population, limited ethnicities, and varied vitamin D dosing strategies across the studies were notable limitations. Conclusions Vitamin D supplementation could be part of our clinical armamentarium when managing IBS patients due to the potential efficacy and good safety profile. Further randomized, controlled trials are required to confirm the therapeutic effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D supplementation for irritable bowel syndrome: A systematic review and meta‐analysis

Chong

Yaow

Loh

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Nowadays the currently used drugs for IBS present variable efficacy and some of them are associated with long-term side effects (Lucak et al, 2017;Patel et al, 2021). Thus, the development of new therapeutic strategies could be of great social and clinical relevance.…”

Section: Resultsmentioning

confidence: 99%

Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats

et al. 2022

View full text Add to dashboard Cite

Ethnopharmacological relevance:Serpylli herba extract (SHE), composed of the aerial parts of wild thyme (Thymus serpyllum L.) (Lamiaceae family), is traditionally used in Europe and North Africa to treat diarrhea, gastric ulcers, intestinal parasites and upper respiratory tract infections. Recently, SHE has generated a great interest for irritable bowel syndrome (IBS) management, probably due to its intestinal anti-inflammatory properties shown in experimental colitis and the fact that its active components could preserve the intestinal barrier integrity, which is altered in patients with IBS.Aim of study: We aimed to test the effects of a SHE in a rat experimental model resembling human IBS.Materials and methods: IBS was provoked by deoxycholic acid (DCA). Rats were then treated with SHE (100 mg/kg) or gabapentin (70 mg/kg) and different inflammatory and gut barrier integrity markers were evaluated. Moreover, several gut hypersensitivity and hyperalgesia determinations were performed.Results: SHE improved referred pain and visceral hypersensitivity. Additionally, SHE enhanced immune status by downregulating of the expression of the pro-inflammatory mediators Il-1β, Il-6, Ifn-γ, Tlr-4, and the inducible enzyme Cox-2, thus inducing visceral analgesia, and promoting the restore of the gut barrier function by upregulating the mucins Muc-2 and Muc-3. These anti-inflammatory effects could be related to its action on mast cells since it significantly inhibited the β-Hexosaminidase production in RBL-2H3 cells. Lastly, SHE also seems to modulate the serotonin pathway by restoring the altered expression of the 5-HT receptors Htr-3 and Htr-4.Conclusion: SHE could be considered a potential new treatment for IBS, since it ameliorates hypersensitivity, visceral hyperalgesia, and inflammation. These beneficial effects may be due to the inhibition of mast cells degranulation and serotonin pathway.

show abstract

“…Symptom-oriented pharmacological treatment algorithms manage many patients with IBS who fail to improve their lifestyle or follow psychological interventions [12]. Notably, single-agent therapy rarely relieves the symptoms in all patients [4,[13][14][15][16][17].…”

Section: Treatment For Ibs: Lack Of Curablementioning

confidence: 99%

Improving the Treatment Response of Patients with Irritable Bowel Syndrome: Implementing a Second-Generation Artificial Intelligence System for Overcoming Resistance

et al. 2022

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a common functional disorder. The syndrome’s multifactorial pathophysiology makes it challenging to design effective therapies. The present paper reviews several therapeutic approaches to treating IBS, highlighting the challenges of losing response over time to therapies. Here, we present the relevance of chronobiology in biological systems focusing on the potential of chronotherapy for IBS. Artificial intelligence- (AI-) based approaches have been developed over the last few years to improve the diagnosis, therapeutic approaches, and monitoring of patients with various diseases. We discuss the use of first-generation AI platforms and their limitations in clinical practice and present the establishment of a second-generation system designed to overcome obstacles in managing these patients. The system identifies costly patients and those who do not respond to therapies and may benefit from algorithm-based therapies. We present a patient-tailored approach for improving the response to therapy in IBS using an AI-based algorithm. This system provides a tool for a patient-tailored monitoring system. The second-generation AI system can provide a comprehensive tool for improving the diagnosis and therapy and monitoring of patients with IBS.

show abstract

Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

Cited by 8 publications

References 46 publications

Vitamin D supplementation for irritable bowel syndrome: A systematic review and meta‐analysis

Vitamin D supplementation for irritable bowel syndrome: A systematic review and meta‐analysis

Intestinal anti-inflammatory and visceral analgesic effects of a Serpylli herba extract in an experimental model of irritable bowel syndrome in rats

Improving the Treatment Response of Patients with Irritable Bowel Syndrome: Implementing a Second-Generation Artificial Intelligence System for Overcoming Resistance

Contact Info

Product

Resources

About